journal
Journals Critical Reviews in Oncology/h...

Critical Reviews in Oncology/hematology

https://read.qxmd.com/read/38762217/tyrosine-kinase-inhibitors-in-cancers-treatment-optimization-part-i
#1
REVIEW
David Combarel, Léa Dousset, Stéphane Bouchet, Florent Ferrer, Pauline Tetu, Céleste Lebbe, Joseph Ciccolini, Nicolas Meyer, Angelo Paci
A multitude of TKI has been developed and approved targeting various oncogenetic alterations. While these have provided improvements in efficacy compared with conventional chemotherapies, resistance to targeted therapies occurs. Mutations in the kinase domain result in the inability of TKI to inactivate the protein kinase. Also, gene amplification, increased protein expression and downstream activation or bypassing of signalling pathways are commonly reported mechanisms of resistance. Improved understanding of mechanisms involved in TKI resistance has resulted in the development of new generations of targeted agents...
May 16, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38754771/emerging-targeted-therapies-and-strategies-to-overcome-resistance-in-biliary-tract-cancers
#2
REVIEW
Tarik Demir, Carolyn Moloney, Devalingam Mahalingam
In the last decade, targeted therapies have shown rapid advancement in biliary tract cancer (BTC). Today, many targeted agents are available and under investigation for patients with BTC. More recently, immune checkpoint inhibitors (ICI) such as durvalumab and pembrolizumab in combination with gemcitabine plus cisplatin (gem/cis) have resulted in improved overall survival and progression-free survival in the first-line setting. However, the efficacy benefit of these novel therapeutics is often short-lived, with literature outlining concerns about both primary and secondary resistance to these agents...
May 14, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38754770/the-relationship-between-ldh-and-glim-criteria-for-cancer-cachexia-systematic-review-and-meta-analysis
#3
REVIEW
Joshua Thompson, Josh McGovern, Campbell Roxburgh, Joanne Edwards, Ross D Dolan, Donald C McMillan
INTRODUCTION: Cancer cachexia is a clinical condition characterized by recognizable "sickness behaviors" accompanied by loss of lean body tissue. The Global Leadership on Malnutrition (GLIM) has proposed phenotypic (unintentional weight loss, low body mass index and low muscle mass) and aetiologic (reduced food intake and inflammation or disease burden) diagnostic criteria. Recent work has suggested serum lactate dehydrogenase (LDH) might represent a 3rd aetiologic criteria. Little is known of its relationship with GLIM...
May 14, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38744416/letter-to-the-editor-regarding-the-article-a-net-work-meta-analysis-of-the-cardiac-safety-for-next-generation-hormonal-agents-in-treating-castration-resistant-prostate-cancer-how-to-choose-drugs-appropriately
#4
LETTER
Susu Zhou, Parissa Alerasool, Che-Kai Tsao
No abstract text is available yet for this article.
May 12, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38735505/safety-and-efficacy-of-liposomal-irinotecan-as-the-second-line-treatment-for-advanced-pancreatic-cancer-a-systematic-review-and-meta-analysis
#5
REVIEW
Brian Shiian Chen, Shu-Yen Chan, Fernand Bteich, Chaoyuan Kuang, Jeffery A Meyerhardt, Kevin Sheng-Kai Ma
INTRODUCTION: The use of nanoliposomal irinotecan (nal-IRI) is a novel regimen for pancreatic cancer, featuring a longer half-life and increased area under the concentration-time curve. However, comprehensive systematic reviews or meta-analyses evaluating its efficacy as a second-line treatment have been scarce. Therefore, this study aims to review the current body of evidence on nal-IRI, assessing its overall clinical performances regarding the disease. METHODS: A systemic literature search was conducted based on articles published before September 26, 2023 in PubMed, Cochrane Library, EMBASE, and Web of Science databases...
May 10, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38735504/combining-immunotherapy-and-radiation-therapy-in-gastrointestinal-cancers-a-review
#6
REVIEW
Diana A Mitrea, Eliza M Froicu, Hans Prenen, Maria A Gambacorta, Paul N Span, Philip Poortmans
INTRODUCTION AND PURPOSE: With a significant global impact, treatment of gastrointestinal (GI) cancers still presents with challenges, despite current multimodality approaches in advanced stages. Clinical trials are expanding for checkpoint inhibition (ICI) combined with radiation therapy (RT). This review intends to offer a comprehensive image of the current data regarding the effectiveness of this association, and to reflect on possible directions to further optimize the results. RESULTS: Several early phase studies demonstrated encouraging potential...
May 10, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38734280/a-review-concerning-the-breast-cancer-related-tumour-microenvironment
#7
REVIEW
Oscar Hernán Rodríguez-Bejarano, Carlos Parra-Lopez, Manuel Alfonso Patarroyo
Breast cancer (BC) is currently the most common malignant tumour in women and one of the leading causes of their death around the world. New and increasingly personalised diagnostic and therapeutic tools have been introduced over the last few decades, along with significant advances regarding the study and knowledge related to BC. The tumour microenvironment (TME) refers to the tumour cell-associated cellular and molecular environment which can influence conditions affecting tumour development and progression...
May 9, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38734279/state-of-the-art-targeting-microsatellite-instability-in-gastrointestinal-cancers
#8
REVIEW
Justin Mencel, Anneke Alves, Vasileios Angelis, Marco Gerlinger, Naureen Starling
DNA mismatch repair (MMR) deficiency and the associated microsatellite instability (MSI) phenotype has become a subject of enormous interest in recent years due to the demonstrated efficacy of immune checkpoint inhibitors (ICI) in advanced tumours. Assessing MSI in patients with gastrointestinal tract (GI) cancers is useful to exclude Lynch syndrome, but also to predict benefit for ICI. Following review of the relevant literature, this review article aims to outline the clinicopathologic spectrum of MSI and mismatch repair deficiency (dMMR) in the GI tract, hepatobiliary system and pancreas and discuss the therapeutic consideration in this disease...
May 9, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38729319/mapping-inter-professional-collaboration-in-oncogenetics-results-from-a-scoping-review
#9
REVIEW
Maria-Eugenia Espinoza-Moya, Jason Robert Guertin, Arthur Floret, Michel Dorval, Julie Lapointe, Jocelyne Chiquette, Karine Bouchard, Hermann Nabi, Maude Laberge
Inter-professional collaboration could improve timely access and quality of oncogenetic services. Here, we present the results of a scoping review conducted to systematically identify collaborative models available, unpack the nature and extent of collaboration proposed, synthesize evidence on their implementation and evaluation, and identify areas where additional research is needed. A comprehensive search was conducted in four journal indexing databases on June 13th, 2022, and complemented with searches of the grey literature and citations...
May 8, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38723838/the-hematopoietic-microenvironment-of-the-fetal-liver-and-transient-abnormal-myelopoiesis-associated-with-down-syndrome-a-review
#10
REVIEW
Jun Miyauchi
Transient abnormal myelopoiesis (TAM) in neonates with Down syndrome is a distinct form of leukemia or preleukemia that mirrors the hematological features of acute megakaryoblastic leukemia. However, it typically resolves spontaneously in the early stages. TAM originates from fetal liver (FL) hematopoietic precursor cells and emerges due to somatic mutations in GATA1 in utero. In TAM, progenitor cells proliferate and differentiate into mature megakaryocytes and granulocytes. This process occurs both in vitro, aided by hematopoietic growth factors (HGFs) produced in the FL, and in vivo, particularly in specific anatomical sites like the FL and blood vessels...
May 7, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38718940/unlocking-the-potential-of-molecular-tumor-boards-from-cutting-edge-data-interpretation-to-innovative-clinical-pathways
#11
REVIEW
Brenno Pastò, Giulia Buzzatti, Clorinda Schettino, Umberto Malapelle, Alice Bergamini, Carmine De Angelis, Lucia Musacchio, Maria Vittoria Dieci, Elisabetta Kuhn, Matteo Lambertini, Anna Passarelli, Angela Toss, Alberto Farolfi, Rossana Roncato, Ettore Capoluongo, Riccardo Vida, Sandro Pignata, Maurizio Callari, Gustavo Baldassarre, Michele Bartoletti, Lorenzo Gerratana, Fabio Puglisi
The emerging era of precision medicine is characterized by an increasing availability of targeted anticancer therapies and by the parallel development of techniques to obtain more refined molecular data, whose interpretation may not always be straightforward. Molecular tumor boards gather various professional figures, in order to leverage the analysis of molecular data and provide prognostic and predictive insights for clinicians. In addition to healthcare development, they could also become a tool to promote knowledge and research spreading...
May 6, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38718939/interactions-between-platelets-and-the-cancer-immune-microenvironment
#12
REVIEW
Nuerye Tuerhong, Yang Yang, Chenyu Wang, Peng Huang, Qiu Li
Cancer is a leading cause of death in both China and developed countries due to its high incidence and low cure rate. Immune function is closely linked to the development and progression of tumors. Platelets, which are primarily known for their role in hemostasis, also play a crucial part in the spread and progression of tumors through their interaction with the immune microenvironment. The impact of platelets on tumor growth and metastasis depends on the type of cancer and treatment method used. This article provides an overview of the relationship between platelets and the immune microenvironment, highlighting how platelets can either protect or harm the immune response and cancer immune escape...
May 6, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38710296/brain-metastasis-an-insight-into-novel-molecular-targets-for-theranostic-approaches
#13
REVIEW
Liliana Santos, João Nuno Moreira, Antero Abrunhosa, Célia Gomes
Brain metastases (BrM) are common malignant lesions in the central nervous system, and pose a significant threat in advanced-stage malignancies due to delayed diagnosis and limited therapeutic options. Their distinct genomic profiles underscore the need for molecular profiling to tailor effective treatments. Recent advances in cancer biology have uncovered molecular drivers underlying tumor initiation, progression, and metastasis. This, coupled with the advances in molecular imaging technology and radiotracer synthesis, has paved the way for the development of innovative radiopharmaceuticals with enhanced specificity and affinity for BrM specific targets...
May 4, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38710295/efficacy-of-natural-products-in-preventing-oral-mucositis-resulting-from-cancer-therapies-a-network-meta-analysis-of-randomized-controlled-trials
#14
REVIEW
Chai-Chun Lee, Yue-Wen Chen, Yi-No Kang, Jin-Hua Chen, Chiehfeng Chen, Chi-Yu Lu, Tsai-Wei Huang, Made Satya Nugraha Gautama
BACKGROUND: Oral mucositis significantly compromises the quality of life for patients undergoing cancer therapies. This study aimed to evaluate the effectiveness of natural products in either preventing or alleviating oral mucositis resulting from cancer treatments. METHODS: A systematic review and network meta-analysis were conducted, sourcing data from the Cochrane Library, PubMed, Embase, Airiti Library, and Wan Fang Data Knowledge Service Platform until August 2023...
May 4, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38692463/comment-on-the-risk-of-breast-cancer-and-gynecologic-malignancies-after-ovarian-stimulation-meta-analysis-of-cohort-study
#15
LETTER
Zhi-Ting Zhang, Wei Han, Xue-Ke Guo, Xing Gu
No abstract text is available yet for this article.
April 29, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38685459/thromboembolic-risk-in-prostate-cancer-patients-treated-with-parp-inhibitors-a-systematic-review-and-meta-analysis
#16
REVIEW
Sati Coskun Yazgan, Erman Akkus, Emre Yekeduz, Yuksel Urun
BACKGROUND: Poly (ADP-ribose) polymerase inhibitors (PARPi) have been associated with thrombotic events, although the association with thrombosis risk in different cancers remains poorly defined. METHODS: This meta-analysis included phase II and phase III clinical trials in which patients with metastatic prostate cancer were treated with PARPi either as monotherapy or in combination. The primary endpoints were the rates of thromboembolic events in prostate cancer patients...
April 27, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38679402/dostarlimab-review-on-success-story-and-clinical-trials
#17
REVIEW
Rohitash Yadav, Ishita Mathur, Hoineiting Rebecca Haokip, Avaneesh K Pandey, Vinod Kumar, Neeraj Jain
The PD-1/PD-L1 pathway plays a significant role in inhibiting, escaping from immune response, and promoting self-tolerance of the tumour. Dostarlimab is a selective humanized monoclonal antibody designed to target PD-1 and block its activity with PD-L1, which further prevents the escape of tumour cells from immune surveillance. It got accelerated approval from the FDA for treating adults with mismatch repair deficient, recurrent, or advanced endometrial cancer, and studies confirmed its beneficial effects. A recently published clinical trial reported 100% remission of advanced rectal cancer without significant side effects in the participants...
April 26, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38677356/evaluation-of-first-line-and-salvage-therapies-for-unresectable-malignant-mesothelioma-a-systematic-review-and-network-meta-analysis
#18
REVIEW
Wei Zhuang, Lihui Liu, Boyang Sun, Hua Bai, Zhijie Wang, Jianchun Duan, Rui Wan, Zixiao Ma, Jia Zhong, Jie Wang
BACKGROUND: Randomized controlled trials (RCTs) of systemic therapies for unresectable malignant mesothelioma have reported conflicting results. It is crucial and urgent to find optimal treatment options for this malignancy, which currently has a poor prognosis. METHODS: Databases PubMed, EMBASE, Cochrane Library, ClinicalTrials.gov, and major international conferences were searched until February 29, 2024. The main outcomes of interest were overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and grade ≥3 treatment-related adverse events (TRAEs)...
April 25, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38677355/unlocking-hope-anti-vegfr-inhibitors-and-their-potential-in-glioblastoma-treatment
#19
REVIEW
Ali Berro, Ahmad Assi, Mohamad Farhat, Lea Hatoum, Jean-Pierre Saad, Rami Mohanna, Anna Maria Antoun Bechara, Gilles Prince, Maria Catherine Rita Hachem, Ziad Zalaquett, Hampig-Raphael Kourie
PURPOSE: This systematic review summarizes evidence of VEGFR gene mutations and VEGF/VEGFR protein expression in glioblastoma multiforme (GBM) patients, alongside the efficacy and safety of anti-VEGFR tyrosine kinase inhibitors (TKIs) for GBM treatment. METHODS: A comprehensive literature review was conducted using PubMed up to August 2023. Boolean operators and MeSH term "glioma," along with specific VEGFR-related keywords, were utilized following thorough examination of existing literature...
April 25, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38657702/radon-and-lung-cancer-current-status-and-future-prospects
#20
REVIEW
Yan Liu, Yanqing Xu, Wei Xu, Zhengzhong He, Cong Fu, Fen Du
Beyond tobacco smoking, radon takes its place as the second most significant contributor to lung cancer, excluding hereditary and other biologically related factors. Radon and its byproducts play a pivotal role in exposing humans to elevated levels of natural radiation. Approximately 10-20% of lung cancer cases worldwide can be attributed to radon exposure, leading to between 3% and 20% of all lung cancer-related deaths. Nevertheless, a knowledge gap persists regarding the association between radon and lung cancer, impeding radon risk reduction initiatives globally...
April 22, 2024: Critical Reviews in Oncology/hematology
journal
journal
20089
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.